Squamous in Biological Technology

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... in patients with inoperable (Stage III or IVa) squamous cell carcinoma of the head and neck (SCCHN). ... radiotherapy plus cetuximab in locally-advanced squamous cell carcinoma of the head and neck, reporting a ... 100mg/m2 d1, 22) in Stage III or IV, M0, squamous cell carcinoma patients. The population in that ...

Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.

... predicted primary origin. - miRview(TM) squamous - Using a single microRNA, miRview(TM) squamous differentiates squamous from non-squamous, non-small cell lung cancer ... available or under development, patients with squamous cell carcinoma of the lung have demonstrated ...

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

... Diagnostic Programs - miRview(TM) squamous - Rosetta has recently completed the ... at its Philadelphia lab. The test differentiates squamous from non squamous non-small cell lung cancer (NSCLC) with high ...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

... human tumor xenografts lacking EGFR expression. squamous Cell Carcinoma of the Head and Neck (SCCHN) ... treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX, ... of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom ...

Rosetta Genomics Reports Second Quarter 2008 Financial Results

... for clinical use. The test, which differentiates squamous from non squamous non-small cell lung cancer (NSCLC) with ... ability of physicians to accurately differentiate squamous from non-squamous NSCLC is an important treatment ...

Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.

... facilities this year: - Differentiating squamous from non-squamous non-small cell lung cancer- This test is designed to differentiate squamous from non-squamous non-small cell lung cancer ... of physicians to accurately differentiate squamous from non-squamous NSCLC is an important treatment ...

Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests

... and validation at Parkway's facility are: - squamous vs. Non squamous non-small cell lung cancer - This test is designed to differentiate squamous from ...

/C O R R E C T I O N -- Rosetta Genomics Ltd/

... of Health. The test is designed to differentiate squamous from non squamous non-small cell lung cancer ... corporate highlights: Diagnostic Programs - squamous vs. Non squamous non-small cell lung cancer (NSCLC) - Columbia ...

Rosetta Genomics Reports First Quarter 2008 Financial Results

... of Health. The test is designed to differentiate squamous from non squamous non-small cell lung cancer ... corporate highlights: Diagnostic Programs - squamous vs. Non squamous non-small cell lung cancer (NSCLC) - Columbia ...

Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference

... microRNA can differentiate squamous from non squamous NSCLC with high sensitivity and specificity. The ability of physicians to accurately differentiate squamous from non-squamous non-small cell lung cancer ... of severe or fatal hemorrhage among patients with squamous NSCLC histology compared with non-squamous ...

Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results

... Avniel said the three tests will differentiate squamous from non-squamous cell lung cancer; differentiate ... corporate highlights: Diagnostic Programs - squamous vs. Non squamous non-small cell lung cancer (NSCLC) - Bevacizumab ...

Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe Technology

... tests to launch in 2008: - Differentiating squamous from non squamous lung cancer - As current targeted therapy for lung cancer can cause hemorrhaging in squamous cell lung cancer patients, differentiating ...

Oncolytics Biotech Inc. Announces 2007 Third Quarter Results

... (oesophageal, squamous skin carcinoma and squamous cell scalp) experienced significant partial ... that was maintained for more than six months. The squamous skin cancer patient experienced a 50% reduction ... at one, two and three months post treatment. The squamous cell scalp patient experienced stable disease in ...

Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial

... (oesophageal, squamous skin carcinoma and squamous cell scalp) experienced significant partial ... that was maintained for more than six months. The squamous skin cancer patient experienced a 50% reduction ... at one, two and three months post treatment. The squamous cell scalp patient experienced stable disease in ...

Lilly Set to Unveil More Than 50 Studies at ASCO 2009

... is not indicated for patients who have a different type of NSCLC called squamous cell. ALIMTA is approved by the FDA as a single agent (used alone) ... is not indicated for patients who have a different type of NSCLC called squamous cell. ALIMTA is a treatment for malignant pleural mesothelioma (MPM), ...

Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso

... patients. miRview(TM) mets is available for $3650. - miRview(TM) squamous - This test differentiates between two subtypes of non small cell lung ... 170,000 patients are diagnosed each year with NSCLC. miRview(TM) squamous is available for $3170. - miRview(TM) meso - This test differentiates ...

Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis

... one patient taking placebo plus methotrexate developed Bowen's disease and squamous cell skin cancer, one patient taking golimumab 100 mg plus placebo ... cancer, and one patient taking golimumab 100 mg plus placebo developed squamous cell carcinoma. One patient receiving golimumab 100 mg plus placebo died ...

PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial

... in the gene that encodes type VII collagen. DEB is characterized by extremely fragile skin, recurrent blister formation, scarring and aggressive squamous cell carcinomas. Keck School of Medicine of the University of Southern California researchers David T. Woodley, M.D. and Mei Chen, Ph.D. have studied ...

It's Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer

... to BCC but protects agains cutaneous melanoma. A previously known SNP in the SLC45A2 gene on chromosome 5 was confirmed to confer risk of squamous cell carcinoma as well as BCC. The study involved three stages. First, the SNPs with the best results from previous genome-wide scans of more than ...

Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results

... in combination with chemotherapy for various cancer indications. These indications are expected to include melanoma, pancreatic cancer, squamous cell lung, liver and K-RAS mutated colorectal cancers in combination with standard chemotherapeutics. Latest Highlights ...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

... a standard first-line NSCLC chemotherapy regimen that included a platinum-based regimen plus gemcitabine. 51% of patients had adenocarcinoma, 16% had squamous cell carcinoma and 33% of patients had undifferentiated or unspecified non-small cell lung cancer. The primary objectives of the study were designed ...

Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55

... a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). The DMC also recommended that patients with squamous NSCLC immediately discontinue motesanib therapy but did not recommend discontinuation of motesanib therapy for patients with non-squamous NSCLC. ...

CEL-SCI Corporation Announces 2008 Financial Results

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. Multikine is also the first immunotherapeutic agent being developed as a first-line ...

YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE

... clinical trial, which will involve approximately 22 institutions from 12 countries worldwide. The trial will treat patients with locally advanced squamous cell cancers of the head and neck immediately following surgery - the "adjuvant setting". Along with standard chemotherapy and radiotherapy, half of ...

Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting

... Melanoma 3x10(9) 2 PD ------------------------------------------------------------------------- squamous cell 3x10(9) 8 Clinical CR, SD per CT carcinoma (SCC) scan head & neck ...

Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting

... 30% reduction in PSA ------------------------------------------------------------------------- squamous Cell 3x10(9) 3 Minor response Carcinoma 26% reduction in Head and Neck ...

CEL-SCI Takes Delivery of New Manufacturing Facility

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. In the summer of 2007 CEL-SCI started construction of the manufacturing facility to produce ...

CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. CEL-SCI is currently building a manufacturing facility for Multikine close to Baltimore, ...

Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV

... primarily on cancer and various women's health indications. The first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical Center's High Complexity Molecular Pathology Laboratory. In Addition, ...

CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. In the summer of 2007 CEL-SCI started construction of the manufacturing facility to produce ...

Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer

... designed to inhibit thioredoxin-1. Increased levels of thioredoxin-1 have been noted in many types of cancer cells, including hepatoma, lung cancers, squamous cervical carcinoma, primary gastric cancers and colorectal carcinomas. Increased levels of thioredoxin-1 are associated with decreased sensitivity to ...

CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. In the summer of 2007 CEL-SCI started construction of the manufacturing facility to produce ...

NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING

... (PD) study of Nimotuzumab, an anti epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): A SENDO Foundation study" (Abstract number 6070): Ten patients with advanced SCCHN, unsuitable for ...

Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis

... CEO of Quest. "Actinic Keratosis is a pre-cancerous skin condition usually caused by prolonged accumulated sun exposure which can progress to squamous cell carcinoma, a potentially life-threatening form of skin cancer, unless treated by a dermatologist or other physician. This trial successfully ...

Lilly Reports Solid First-Quarter Results

... approved Alimta in combination with cisplatin as a first-line treatment for non-small-cell lung cancer patients with other than predominantly squamous cell histology. -- The company, along with its partner, Amylin Pharmaceuticals, Inc., submitted Byetta as a monotherapy treatment for type 2 ...

Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo

... profound single agent efficacy in a broad spectrum of chemotherapy refractory cancers, including pancreatic cancer, breast cancer, colon cancer, squamous cell carcinoma of larynx, uterine cancer, gastric cancer, malignant melanoma, validating Epeius Biotechnologies' in vivo targeted gene delivery ...

Helix BioPharma Corp. announces fiscal 2007 results

... - Announced positive Phase II clinical results with Topical Interferon Alpha-2b in patients with HPV-induced low-grade squamous intraepithelial lesions ("LSIL") - Initiated enrollment in Phase II clinical trial with Topical Interferon Alpha-2b in patients with ...

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference

... which targets melanoma-associated chondroitin sulfate proteoglycan (MCSP). MT110 is being developed for the treatment of a variety of adeno and squamous cell carcinoma which overexpress EpCAM, while the BiTE antibody which binds to MCSP is being developed for the treatment of metastatic melanoma and ...

CEL-SCI to Present at the Noble Financial Conference

... the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. Multikine, a patented defined mixture of naturally derived cytokines, is the first ...